Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Alexandre BazinetSai Prasad DesikanZiyi LiJuan José Rodríguez SevillaSangeetha VenugopalSamuel Urrutia ArguetaGuillermo Montalban BravoKoiji SasakiKelly Sharon ChienDanielle HammondRashmi Kanagal-ShamanaIrene Gañán-GómezTapan Mahendra KadiaGautam BorthakurCourtney D D DiNardoNaval G DaverElias J JabbourFarhad RavandiHagop M KantarjianGuillermo Garcia ManeroPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.